Balanced news tone
News Sentiment
CNTA sentiment intelligence
Centessa Pharmaceuticals PLC ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
72/100 classification confidence.
directly relevant articles
high-authority source matches
+1.2% over one week, +1.9% over four weeks, trend active, and materially above fair value.
FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA)
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 14:12
- Source
- Stock Titan
[15-12G] Centessa Pharmaceuticals plc SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 13:30
- Source
- Stock Titan
Eli Lilly acquisition cancels Centessa (NASDAQ: CNTA) director stock options for cash and CVRs
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Eli Lilly buys Centessa (NASDAQ: CNTA) as director options convert to cash and CVRs
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Eli Lilly deal cancels Centessa Pharmaceuticals (CNTA) director share options
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Centessa (NASDAQ: CNTA) CEO’s shares and options canceled in Eli Lilly cash-and-CVR deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Eli Lilly deal cashes out Centessa (CNTA) CMO’s entire equity stake
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Eli Lilly buys Centessa (CNTA); CFO shares and options canceled
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Centessa Pharmaceuticals (CNTA) holders get $38 cash plus CVR in Eli Lilly buyout
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Farallon discloses 6.1% Centessa (NASDAQ: CNTA) ownership stake
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Centessa (NASDAQ: CNTA) bought by Eli Lilly for $38 plus CVR
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
[POSASR] Centessa Pharmaceuticals plc SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Eli Lilly acquisition converts Centessa (NASDAQ: CNTA) director options into $38 cash plus CVRs
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Centessa Pharmaceuticals (CNTA) Nasdaq ADSs Withdrawn from Listing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Centessa (CNTA) CAO cashed out as Eli Lilly acquires all shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 01 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView